(Boursier.com) — Ipsen announces growth in the Group’s total sales in 2023, up 6.7% at constant exchange rate (3.4% in published data) to €3.127 billion, driven by the performance of growth platforms and the contribution of new drugs. The operating margin of the activities which stands at 32% (IFRS operating margin at 26.1%) was achieved in a context of increased investments in ‘R&D’ mainly linked to recent acquisitions. Free cash flow fell by 13% to €710.9 million. The IFRS consolidated net result came to €647.2 million.
The financial objectives for the year 2024 include growth in total group sales of more than 6% at constant exchange rate and an operating margin of around 30% including the impact of four potential launches and a portfolio of reinforced ‘R&D’ products.
“The strong results of the year have built an excellent foundation for Ipsen in 2024, an exciting period where we anticipate four launches and new opportunities to expand the ‘R&D’ product portfolio” said David Loew, Director general of Ipsen. “As Ipsen continues its transformation, advancements in execution have supported continued sales growth, while our R&D product portfolio has delivered promising results for patients.
Our external innovation strategy, supported by a strong balance sheet, continues to increase the number of potential medicines available to us across our three therapeutic areas. After the acquisition of Albireo in 2023 and the successful launch of Bylvay, we hope to achieve further milestones this year and continue to increase our product portfolio by carrying out further external innovation operations. Given the success of our strategy and positioning, I am confident in our ability to bring more medicines to patients and ensure Ipsen’s sustainable growth.”
©2024 Boursier.com